U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07169578) titled 'A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease' on Sept. 10.
Brief Summary: The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
Study Start Date: Oct. 27
Study Type: INTERVENTIONAL
Condition:
Alzheimers Disease
Intervention:
DRUG: Trontinemab
Participants will receive IV trontinemab.
OTHER: Placebo
Participants will receive IV placebo.
Recruitment Status: RECRUITING
Sponsor: Hoffmann-La Roche
Disclaimer: Curated by HT Syndication....